> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# ARK Holds 5.54% Of Prime Medicine Without A Bid To Influence Control
- URL: https://www.bullished.co/ark-holds-5-54-of-prime-medicine-without-a-bid-to-influence-control-daed327f/
- Published: 2026-11-13T17:55:57.000Z
- Updated: 2026-11-13T17:55:57.000Z
- Description: The investment manager reported more than 10 million shares in the developer of DNA-editing medicines.
- Author: Matteo Parrino
- Tags: SEC Filings, PRME, Industry: Healthcare, Topic: Ownership & Activism

ARK Investment Management reported Friday that it held a [5.54% stake](https://www.sec.gov/Archives/edgar/data/0001697748/000110465926126830/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) in [Prime Medicine](https://www.bullished.co/tag/prme/), which develops genetic medicines that rewrite DNA to correct disease-causing changes. Its SEC passive ownership disclosure certified that the shares were held for ordinary business purposes without an intent to change or influence control.

## One Holding, Shared Reporting

ARK reported 10,043,508 common shares as of September 30, 2026\. Catherine D. Wood, the investment manager's chief executive officer and chief investment officer, was a [joint reporting person](https://www.sec.gov/Archives/edgar/data/1697748/000110465926126830/tm2629184d8%5Fex1.htm?ref=bullished.co) for the same holding.

ARK had [sole voting power](https://www.sec.gov/Archives/edgar/data/0001697748/000110465926126830/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) over those shares; Wood reported shared voting power over the same shares. The ownership figures describe the same position, not separate holdings to be added together.

ARK's exchange-traded funds hold concentrated positions in small and midsize companies, frequently exceeding the 5% ownership threshold. That pattern has produced about 170 ownership schedules over two years.

PRME shares soared about 12% to $4.35 in Friday trading versus the prior close. Prime Medicine's market value was $706 million in Friday trading.

## DNA Editing And Licensing Revenue

Prime Medicine combines its own treatment-development programs with research and licensing partnerships. Its Prime Editing technology is designed to correct disease-causing DNA changes.

The company's wholly owned programs target liver diseases, including Wilson disease and alpha-1 antitrypsin deficiency. It also conducts cystic fibrosis research and has a clinical program for chronic granulomatous disease.

Bristol-Myers Squibb licenses Prime Medicine's technology to develop treatments using immune cells edited outside the body. The collaboration, signed in September 2024, brought Prime Medicine a $55 million upfront payment.

The Cystic Fibrosis Foundation provides development funding for the company's cystic fibrosis work.

Learn

- [13D Filing Requirements And Deadline, Shown With Real Filings →](https://www.bullished.co/learn/13d-filing-requirements/)  
A Schedule 13D is required when you own more than 5% of a public company's voting shares. See the deadline, contents and real filings from this week.
- [13D Vs 13G: What Each 5% Stake Filing Means And How To Read One →](https://www.bullished.co/learn/13d-vs-13g/)  
13D vs 13G: both report stakes above 5%, but 13G is the short passive form and 13D explains intent. See real BlackRock and Pictet filings read in plain English.

### Sources

- [SCHEDULE 13G — ARK Investment Management LLC re: Prime Medicine, Inc. (PRME)](https://www.sec.gov/Archives/edgar/data/0001697748/000110465926126830/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) — SEC EDGAR
- [SCHEDULE 13G Exhibit 1 — EXHIBIT 1](https://www.sec.gov/Archives/edgar/data/1697748/000110465926126830/tm2629184d8%5Fex1.htm?ref=bullished.co) — SEC EDGAR

### More on Prime Medicine

- [Prime Medicine Expects Funding Through 2027 As Its Liver Treatments Move Into Human Testing](https://www.bullished.co/prime-medicine-expects-funding-through-2027-as-its-liver-treatments-move-into-human-0a975bc9/)
- [Prime Medicine Prices $125 Million Offering At $3.50 To Fund Liver-Disease Research](https://www.bullished.co/prime-medicine-prices-125-million-offering-at-3-50-to-fund-liver-disease-research-4cd78edf/)
- [Prime Medicine Estimates $61.2 Million In Liquidity With Liver Trial Results Expected In 2027](https://www.bullished.co/prime-medicine-estimates-61-2-million-in-liquidity-with-liver-trial-results-expected-in-5f7da437/)

[All Prime Medicine (PRME) coverage →](https://www.bullished.co/tag/prme/)